Glafenine HCl

Glafenine HCl (CAS No.: 65513-72-6) is a synthetic small molecule in the nonsteroidal anti inflammatory research class that is broadly categorized as a cyclooxygenase pathway modulator, with reported nonselective inhibitory activity toward COX 1 and COX 2 and downstream suppression of arachidonic acid derived prostaglandin biosynthesis, supporting its use as a tool compound for investigating inflammatory signaling networks, cell proliferation control, and migration associated biology in biomedical discovery settings; available evidence further indicates effects on vascular cell phenotypes, including induction of cell cycle arrest in vascular smooth muscle and endothelial cell systems and reduced production of extracellular matrix associated tenascin, which positions this agent in mechanistic studies of inflammation linked tissue remodeling and restenosis related processes, while also being relevant to exploratory pathway interrogation in disease biology areas such as cystic fibrosis research; because standardized potency datasets are not consistently reported across platforms for this specific entry, in vitro activity is generally described at low micromolar to micromolar concentration ranges in pharmacology style assay designs, and the compound is commonly applied in cell based experiments, phenotypic profiling workflows, and preclinical model hypothesis testing where concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, with interpretation focused on target pathway modulation, biomarker shifts, and structure activity informed screening rather than any human use context.